MedPath

Maternal Marijuana Use and Fetal and Infant Outcome

Withdrawn
Conditions
Cannabis Use Disorder
Pregnancy Related
Registration Number
NCT04266314
Lead Sponsor
Johns Hopkins University
Brief Summary

Marijuana and cannabis-containing products are growing in popularity and availability in the United States, and use during pregnancy has increased dramatically. The overarching aim of this proposal is to provide pilot data for a submission which will explore the impact of chronic maternal marijuana use (primary or secondary) on fetal functioning, maternal reflective functioning and infant birth and neurodevelopmental outcomes. Chronically marijuana using pregnant women in treatment at the Center for Addiction and Pregnancy will be enrolled and asked to provide information about participants' marijuana and other licit and illicit substance use and feelings about parenting and participants' infant and undergo fetal monitoring at 36 weeks gestation. The neonates will undergo neurobehavioral examination during the first and fourth weeks of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Singleton pregnancy less than 36 weeks of gestation
  • Marijuana as a primary or secondary drug of choice

Maternal

Exclusion Criteria
  • Significant fetal anomaly
  • Multiple gestation
  • Delivery prior to 36 weeks gestation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in infant neurobehavioral functioning as assessed by the NICU Network Neurobehavioral ScaleOne day during week 1 and week 4 of infant life

Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale scores.

Change in Prevalence of maternal cannabis use disorderThe first day of study enrollment and again at infant delivery

Rates of Cannabis use disorder among pregnant women reporting primary or secondary (i.e. first or second drug of choice) cannabis use during pregnancy.

Infant head circumference at birthAt the time of delivery

Infant head circumference in centimeters

Infant weight at birthAt the time of delivery

Birth weight in kilograms

Fetal functioning as assessed by fetal heart rateOne day during 36th weeks of gestation

Fetal heart rate in beats per minute will be measured.

Infant Apgar Score at 1 minuteAt 1 minute after delivery

Apgar Score after birth at one minute; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.

Infant Apgar Score at 5 minutesAt 5 minutes after delivery

Apgar Score after birth at five minutes; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.

Fetal functioning as assessed by fetal movementOne day during 36th weeks of gestation

Fetal movement: number and length in msecs of bouts of fetal movement as determined by fetal actograph testing

Change in Maternal reflective functioning as assessed by the Parental Reflective Functioning QuestionnaireAt 36 weeks of gestation, postpartum week 1, postpartum week 4

Responses that evaluate the mother's ability to reflect on and interpret her own behavior and that of her child in terms of mental states and intentions; this will be assessed using the Parental Reflective Functioning Questionnaire.

Infant length at birthAt the time of delivery

Infant length in centimeters

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Johns Hopkins Bayview Medical Center

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath